From Nasdaq: 2025-05-22 08:34:00

Investors in ADMA Biologics, Inc. ADMA should take note of the stock’s options market activity, particularly the high implied volatility of the Aug 15, 2025 $10.00 Put. Implied volatility indicates expected future market movement, suggesting a potential big move. Analysts have a mixed view, with no upward revisions in estimates for the current quarter.

The Zacks Consensus Estimate for ADMA Biologics’ current quarter has decreased from 16 cents to 14 cents per share over the last 60 days. This has led to a Zacks Rank #3 (Hold) for the company in the Medical – Biomedical and Genetics industry. The high implied volatility may present a trading opportunity, especially for premium selling strategies.

Zacks Executive VP Kevin Matras offers a powerful options trading approach that has delivered double and triple-digit winners. For just $1, you can access all Zacks’ picks for 30 days to explore services like Surprise Trader, Stocks Under $10, and Technology Innovators, with a track record of significant gains.

Thousands have already benefited from Zacks’ $1 offer to access all picks for 30 days, discovering opportunities like the 256 double- and triple-digit gains in 2024. Explore Zacks’ latest stock recommendations and analysis to make informed investment decisions. Click to see Zacks’ picks for the next 30 days for free.



Read more at Nasdaq: Are Options Traders Betting on a Big Move in ADMA Biologics Stock?